HCV Care & Guidance HCV Care & Guidance HCV Care & Guidance PDF Print PDF Print
      HCV Care & Guidance
         Practical Education and Resources
  1. Course List
Co-Chairs
faculty image
Sherilyn C. Brinkley, MSN, CRNP
  • Nurse Practitioner/ Program Manager
  • Infectious Disease Department
  • Johns Hopkins University
  • Baltimore, Maryland
    • faculty image
    Jill Y. Chang, PA-C
  • Physician Assistant
  • Division of Gastroenterology/Hepatology
  • Scripps Clinic Torrey Pines
  • La Jolla, California
    • In May 2011, the FDA approved two new drugs for the treatment of chronic hepatitis C infection: boceprevir and telaprevir. These drugs, when combined with peginterferon and ribavirin, offer significantly higher response rates and shorter durations of therapy compared with the current standard of care therapy and give new hope to HCV-infected patients.

    HCV Care & Guidance: Practical Education and Resources for Nurse Practitioners and Physician Assistants will help prepare your office, staff, and patients for this new treatment opportunity. A free online program, HCV Care & Guidance includes 10 separate activities and numerous practical resources that are designed to deliver an integrated learning experience covering the clinical issues related to direct-acting antiviral (DAA) therapy.

  • Assess the importance of screening and diagnosing all patients at risk for HCV in order to implement interventions that minimize or prevent cirrhosis/HCC and improve patient outcomes.
  • Analyze factors associated with nonresponse, partial response, and relapses in patients receiving anti-HCV treatment as well as treatment options in order to select and apply strategies that improve treatment response.
  • Assess current anti-HCV therapies and treatment strategies in chronically HCV-infected patients (including nonresponders, partial responders, and relapsers) by analyzing efficacy and safety data, duration of treatment, and side-effect management.
  • Contrast safety, adverse effects, and potential drug-drug interactions of emerging DAA HCV therapies in order to formulate potential treatment and management strategies integrating response-guided therapy, on-treatment milestones, and tailored therapy for different patient types.
  • Implement monitoring strategies to ensure adherence to therapy, adequate dosing, treatment response, virologic breakthrough, side effects, and resistance in order to implement steps to improve patient outcomes.

    • Target Audience

    This CME/CE activity has been designed for nurses, nurse practitioners, physician assistants, hepatologists, gastroenterologists, infectious disease specialists, and pharmacists involved in the care of patients with HCV or those at risk of acquiring the infection.

     

    Activity Goal

    The goal of this activity is to address the needs of nurse practitioners and physician assistants for information and practical instruction regarding new direct-acting antiviral (DAA) therapies for hepatitis C and their integration into clinical practice.